The protective effect of adenosine A2A receptor antagonism in cerebral ischemia

Neurological Research

Volumn 27, Issue 2, 2005, Pages 169-174

  Pedata, F ^a   Gianfriddo, M ^a   Turchi, D ^a   Melani, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

A2A receptor; Adenosine; Cerebral ischemia; Neurological deficit

Indexed keywords

4 AMINOBUTYRIC ACID; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ASPARTIC ACID; ENKEPHALIN; EXCITATORY AMINO ACID; GLUTAMIC ACID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TAURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EVALUATION; EXPERIMENTAL MODEL; EXTERNAL CAROTID ARTERY; HISTOPATHOLOGY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; RAT; REVIEW; TECHNIQUE;

ANIMALS; ASPARTIC ACID; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; HYPOXIA, BRAIN; NEUROPROTECTIVE AGENTS; RECEPTOR, ADENOSINE A2A; TIME FACTORS;

EID: 15244351970     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164105X21913     Document Type: Review

References (53)

1. Hunter AJ, Green AR, Cross AJ. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol Sci 1995; 16: 123-128
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-397
3. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91
4. Melani A, Pantoni L, Corsi C, et al. Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: correlations with neurological deficit and histopathological damage. Stroke 1999; 30: 2448-2454
5. Garcia JH, Wagner S, Liu KF, et al. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995; 26: 627-634
6. 2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 2003; 959: 243-250
7. 2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci 1994; 55: L61-L65
8. 2A adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 1995; 705: 79-84
9. Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? Trends Pharmacol Sci 1998; 19: 59-66
10. Ossowska K. Interaction between striatal excitatory amino acid and gamma-aminobutyric acid (GABA) receptors in the turning behaviour of rats. Neurosci Lett 1995; 202: 57-60
11. Mileson BE, Schwartz RD. The use of locomotor activity as a behavioral screen for neuronal damage following transient forebrain ischemia in gerbils. Neurosci Lett 1991; 128: 71-76
12. Babcock AM, Baker DA, Lovec R. Locomotor activity in the ischemic gerbil. Brain Res 1993; 625: 351-354
13. Rogers DC, Campbell CA, Stretton JL, et al. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 1997; 28: 2060-2065
14. Garcia JH, Liu KF, Ho KL. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke 1995; 26: 636-642
15. Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 2001; 79: 463-484
16. Latini S, Corsi C, Pedata F, et al. The source of brain adenosine outflow during ischemia and electrical stimulation. Neurochem Int 1995; 27: 239-244
17. Dunwiddie TV, Diao L. Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J Pharmacol Exp Ther 1994; 268: 537-545
18. Latini S, Bordoni F, Pedata F, et al. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 1999; 127: 729-739
19. Latini S, Bordoni F, Corradetti R, et al. Temporal correlation between adenosine outflow and synaptic potential inhibition in rat hippocampal slices during ischemia-like conditions. Brain Res 1998; 794: 325-328
20. Kitagawa H, Mori A, Shimada J, et al. Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol Res 2002; 24: 317-323
21. von Lubitz DK. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur J Pharmacol 1999; 365: 9-25
22. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990; 70: 761-845
23. Ribeiro JA, Sebastiao AM, de Mendonca A. Participation of adenosine receptors in neuroprotection. Drug News Perspect 2003; 16: 80-86
24. 2A receptor agonist and antagonist. Eur J Pharmacol 1995; 287: 295-302
25. Bona E, Aden U, Gilland E, et al. Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology 1997; 36: 1327-1338
26. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 1998; 9: 3955-3959
27. 2A receptor agonists and antagonists. Neuroscience 1998; 85: 229-237
28. 2A receptor antagonist. Brain Res 1998; 800: 328-335
29. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999; 19: 9192-9200
30. Belayev L, Alonso OF, Busto R, et al. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 1996; 27: 1616-1622
31. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996; 16: 932-940
32. 2A-receptors. Glia 1996; 18: 152-160
33. 2A adenosine receptor antagonist. Drug Develop Res 1997; 42: 53-70
34. Dixon AK, Gubitz AK, Sirinathsinghji DJ, et al. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996; 118: 1461-1468
35. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991; 57: 1062-1067
36. 2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992; 14: 186-195
37. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001; 431: 331-346
38. Popoli P, Betto P, Reggio R, et al. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 1995; 287: 215-217
39. Golembiowska K, Zylewska A. Adenosine receptors-the role in modulation of dopamine and glutamate release in the rat striatum. Pol J Pharmacol 1997; 49: 317-322
40. 2A receptor stimulation on GABA release from the striatum of young and aged rats in vivo. Neuroreport 1999; 10: 3933-3937
41. Simpson RE, O'Regan MH, Perkins LM, et al. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists. J Neurochem 1992; 58: 1683-1690
42. 2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport 2000; 11: 2591-2595
43. 2A receptors reduces transmitter outflow. Neurobiol Dis 2004; 17: 77-88
44. Cha JH, Frey AS, Alsdorf SA, et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil Trans Roy Soc Lond B Biol Sci 1999; 354: 981-989
45. Zeron MM, Hansson O, Chen N, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002; 33: 849-860
46. Flavin MP, Ho LT. Propentofylline protects neurons in culture from death triggered by macrophage or microglial secretory products. J Neurosci Res 1999; 56: 54-59
47. Neary JT, Zhu Q, Kang Y, et al. Extracellular ATP induces formation of AP-1 complexes in astrocytes via P2 purinoceptors. Neuroreport 1996; 7: 2893-2896
48. Vitolo OV, Ciotti MT, Galli C, et al. Adenosine and ADP prevent apoptosis in cultured rat cerebellar granule cells. Brain Res 1998; 809: 297-301
49. Fredholm BB. Adenosine and neuroprotection. Int Rev Neurobiol 1997; 40: 259-280
50. Jacobson KA, Hoffmann C, Cattabeni F, et al. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis 1999; 4: 197-211
51. 2A receptor involves activation of both N- and P-type calcium channels by different C proteins and protein kinases in the same striatal nerve terminals. J Neurochem 1996; 67: 374-381
52. 2+ uptake through class A calcium channels in rat hippocampal CA3 but not CA1 synaptosomes. Neurosci Lett 1997; 238: 73-77
53. 2B receptor recruits divergent pathways to regulate ERK1/2 and p38. Exp Cell Res 2003; 290: 168-176